NCT04916548View on ClinicalTrials.gov

Repeated Neurocognitive Measurements in Depressed Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

July 15, 2023

Study Completion Date

August 15, 2023

Conditions
Depression, Unipolar
Interventions
DRUG

Intravenous Ketamine

Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)

Trial Locations (1)

15213

Western Psychiatric Institute and Clinic, Pittsburgh

All Listed Sponsors
lead

Rebecca Price

OTHER

NCT04916548 - Repeated Neurocognitive Measurements in Depressed Patients | Biotech Hunter | Biotech Hunter